<aside> <img src="/icons/stars_blue.svg" alt="/icons/stars_blue.svg" width="40px" /> Value proposition
Next-generation Peptide Antibiotics (first-in class) : ADT-340 and ADT-117
Overcomimg the major causes of antibiotic failure by the strong bactericidal action of peptide antibiotics
(Antimicrobial resistance, lack of broad-spectrum antibacterial effect, antibiotic tolerance and biofilm formation)
o A new peptide backbone and novel molecular targets (the non-proteogenic lipids)
o Low chance of antibiotic tolerance (a bactericidal effect on both growing and non-growing bacteria)
o Low chance of biofilm formation (Kills bacteria within a short time)
o Target bacteria : CRPA, CRAB, MRSA and VRSA
o Target patients : ① > 65 years patients (an existing antibiotic + ADT-peptide)
② hospital-acquired infections (CRPA, CRAB and MRSA)
</aside>
<aside> <img src="/icons/stars_blue.svg" alt="/icons/stars_blue.svg" width="40px" /> Indications: sepsis, foot ulcer and wound
</aside>
<aside> <img src="/icons/stars_blue.svg" alt="/icons/stars_blue.svg" width="40px" /> 2022. 03. Company establishment (start-up at Korea University)
</aside>
Bacterial Detection in Water (진단)
PDC (Peptide-drug Conjugates for Cancer Treatment)
Address : 서울 성동구 성수동 2가 제이제이 빌딩 3064 호
Tel : 02-539-6940
Address : JJ building 3064, Seongsu-dong 2-ga , Seongdong-gu, Seoul, Korea
Phone : +82 2-539-6940
E-mail : [email protected] or [email protected]